¼¼°èÀÇ ÀÚ°¡¹é½Å ½ÃÀå : ¾÷°è ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2025-2032³â)
Autogenous Vaccines Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
»óǰÄÚµå
:
1701663
¸®¼Ä¡»ç
:
Persistence Market Research
¹ßÇàÀÏ
:
2025³â 04¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 214 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°è ÀÚ°¡¹é½Å ½ÃÀå ±Ô¸ð´Â 2025³â¿¡ 1¾ï 5,210¸¸ ´Þ·¯¿¡ À̸£°í, 2025-2032³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 5.4%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 2032³â¿¡´Â 2¾ï 1,970¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÚ°¡¹é½ÅÀº ƯÁ¤ °³Ã¼ ¶Ç´Â ¹«¸®¿¡¼ ºÐ¸®µÈ ƯÁ¤ º´¿øÃ¼¿¡ ´ëÇØ °³¹ßµÈ ¸ÂÃãÇü ¹é½ÅÀ¸·Î, ÁÖ·Î ¼öÀÇÇп¡¼ »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ ¹é½ÅÀº °¡Ãà°ú ¹Ý·Áµ¿¹°ÀÇ °¨¿°º´À» ÅëÁ¦ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀº µ¿¹°º´¿ø, µ¿¹°º¸°Ç¼¾ÅÍ, ³óÀå, ¿¬±¸¼Ò¿¡ °ø±ÞµÇ¸ç °¡±Ý·ù, µÅÁö, ¼Ò, ¾ç½Ä¾÷ ºÐ¾ß¿¡¼ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½ÃÀå È®´ë´Â µ¿¹° °Ç°¿¡ ´ëÇÑ °ü½É Áõ°¡, ±ÔÁ¦ À¯¿¬¼º, ƯÈ÷ °¨¿°¼º ÁúȯÀÌ ÈçÇÑ Áö¿ª¿¡¼ Á¤¹ÐÇÑ ¼öÀÇÇÐÀû Áø·á¿¡ ´ëÇÑ °ü½É Áõ°¡°¡ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
¼¼°è ÀÚ°¡¹é½Å ½ÃÀåÀº Àμö°øÅëÀü¿°º´ ¹× °¡ÃàÀü¿°º´ÀÇ ¹ß»ý·ü Áõ°¡, Ç¥ÀûÈµÈ ±ºÁýº° ¿¹¹æÁ¢Á¾ÀÇ Çʿ伺 µîÀÇ ÁÖ¿ä ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹é½ÅÀº Ç¥ÁØ »ó¿ë ¹é½ÅÀ¸·Î´Â ´ëÀÀÇÒ ¼ö ¾ø´Â Áö¿ªÀû º´¿øÃ¼ ±ÕÁÖ¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â È¿°úÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. °íǰÁú µ¿¹°¼º ´Ü¹éÁú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, °¡ÃàÀÇ »ý»ê¼º Çâ»ó, ¹«Ç×»ýÁ¦ À°·ù Á¦Ç°¿¡ ´ëÇÑ ¼ÒºñÀÚ ¼±È£µµ°¡ ÀÚ°¡¹é½ÅÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø°ú ¼öÀÇ»ç ¹× °¡Ãà ¼ÒÀ¯ÁÖµé »çÀÌ¿¡¼ ¸ÂÃãÇü Áúº´ °ü¸®¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁø °Íµµ ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾ç½Ä »ê¾÷ÀÇ ¼ºÀåÀº Á¾º° ÀÚ°¡¹é½Å¿¡ ´ëÇÑ »õ·Î¿î ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.
¾çÈ£ÇÑ ¼ºÀå¼¼¿¡µµ ºÒ±¸Çϰí, ÀÚ°¡¹é½Å ½ÃÀåÀº ³ôÀº Á¦Á¶ ºñ¿ë, ¹é½Å °³¹ß ±â°£ÀÇ Àå±âÈ, Á¦Á¶ ¹æ¹ýÀÇ Ç¥ÁØÈ Áö¿¬ µî ¸î °¡Áö Á¦¾à ¿äÀο¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹é½ÅÀº ÁÖ¹® Á¦ÀÛÀ̱⠶§¹®¿¡ ´ë·® »ý»êÀÇ È®À强ÀÌ ºÎÁ·ÇÏ¿© °ø±Þ¸ÁÀÇ È¿À²¼º°ú ºñ¿ë È¿À²¼º¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áö¿ª¸¶´Ù ±ÔÁ¦°¡ ´Ù¸£±â ¶§¹®¿¡ ±¹Á¦ °Å·¡ ¹× ½ÃÀå È®´ë¿¡ ¾î·Á¿òÀÌ ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï±¹ ½ÃÀå¿¡¼´Â ¼Ò±Ô¸ð ³ó°¡¿¡¼ ÀÚ°¡¹é½ÅÀÇ ÇýÅÿ¡ ´ëÇÑ ÀνÄÀÌ ºÎÁ·Çϰí, º´¿øÃ¼ ½Äº°À» À§ÇÑ °í±Þ Áø´Ü µµ±¸ÀÇ °¡¿ë¼ºÀÌ Á¦ÇÑÀûÀ̶ó´Â Á¡µµ ½ÃÀå ħÅõ¿¡ ¶Ç ´Ù¸¥ Àå¾Ö¹°ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.
ÀÚ°¡¹é½Å ½ÃÀåÀº º´¿øÃ¼ µ¿Á¤, ¹é½Å Á¦ÇüÈ, ¸ÂÃãÇü ¼öÀÇÇÐ Ä¡·áÀÇ ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ Å« ±âȸ¸¦ âÃâÇÒ ¼ö ÀÖ´Â ½ÃÀåÀÔ´Ï´Ù. Â÷¼¼´ë ½ÃÄö½Ì ¹× ºÐÀÚÁø´Ü µµ±¸ÀÇ Ã¤ÅÃÀº º´¿øÃ¼ ÇÁ·ÎÆÄÀϸµÀÇ ¼Óµµ¿Í Á¤È®¼ºÀ» Çâ»ó½ÃÄÑ ½Å¼ÓÇÑ ¹é½Å °³¹ßÀ» ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. Ç×±ÕÁ¦ ³»¼º °¨¼Ò¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í Áö¼Ó °¡´ÉÇÑ Ãà»ê¾÷À¸·ÎÀÇ ÀüȯÀº ÀÚ°¡¹é½ÅÀÇ »õ·Î¿î ¼ºÀåÀÇ ±æÀ» ¿¾îÁÙ °ÍÀÔ´Ï´Ù. µ¿¹°¿ë ¹é½Å Á¦Á¶¾÷ü, Áø´Ü ½ÇÇè½Ç, Çмú ±â°üÀÇ Àü·«Àû Á¦ÈÞ´Â ½ÃÀå ¿ª·®À» È®´ëÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ¶ÇÇÑ, ƯÈ÷ ½ÅÈï ½ÃÀå¿¡¼ µ¿¹° À§»ý ÀÌ´Ï¼ÅÆ¼ºê¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø Áõ°¡¿Í ¼öÀÇÇÐ ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ°¡ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼°èÀÇ ÀÚ°¡¹é½Å ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ±ÕÁÖ À¯Çüº°/µ¿¹° À¯Çüº°/ÃÖÁ¾»ç¿ëÀÚº°/Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÃâ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå °³¿ä
- ½ÃÀå ¹üÀ§¿Í Á¤ÀÇ
- ½ÃÀå ¿ªÇÐ
- °Å½Ã°æÁ¦ ¿äÀÎ
- COVID-19ÀÇ ¿µÇ⠺м®
- ¿¹Ãø ¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
Á¦3Àå ºÎ°¡°¡Ä¡ ÀλçÀÌÆ®
Á¦4Àå ¼¼°èÀÇ ÀÚ°¡¹é½Å ½ÃÀå Àü¸Á
- ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
- ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø
- °ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, 2019³â-2024³â
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, 2025³â-2032³â
- ¼¼°èÀÇ ÀÚ°¡¹é½Å ½ÃÀå Àü¸Á : ÁÖ½Ä À¯Çüº°
- ¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
- °ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, ÁÖ½Ä À¯Çüº°, 2019³â-2024³â
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, ÁÖ½Ä À¯Çüº°, 2025³â-2032³â
- ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ÁÖ À¯Çüº°
- ¼¼°èÀÇ ÀÚ°¡¹é½Å ½ÃÀå Àü¸Á : µ¿¹° À¯Çüº°
- ¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
- °ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, µ¿¹° À¯Çüº°, 2019³â-2024³â
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, µ¿¹° À¯Çüº°, 2025³â-2032³â
- ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : µ¿¹° À¯Çüº°
- ¼¼°èÀÇ ÀÚ°¡¹é½Å ½ÃÀå Àü¸Á : ÃÖÁ¾»ç¿ëÀÚº°
- ¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
- °ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, ÃÖÁ¾»ç¿ëÀÚº°, 2019³â-2024³â
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, ÃÖÁ¾»ç¿ëÀÚº°, 2025³â-2032³â
- ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°
Á¦5Àå ¼¼°èÀÇ ÀÚ°¡¹é½Å ½ÃÀå Àü¸Á : Áö¿ªº°
- ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
- °ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, Áö¿ªº°, 2019³â-2024³â
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, Áö¿ªº°, 2025³â-2032³â
- ºÏ¹Ì
- À¯·´
- µ¿¾Æ½Ã¾Æ
- ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾Æ
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Áö¿ªº°
Á¦6Àå ºÏ¹ÌÀÇ ÀÚ°¡¹é½Å ½ÃÀå Àü¸Á
Á¦7Àå À¯·´ÀÇ ÀÚ°¡¹é½Å ½ÃÀå Àü¸Á
Á¦8Àå µ¿¾Æ½Ã¾ÆÀÇ ÀÚ°¡¹é½Å ½ÃÀå Àü¸Á
Á¦9Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ ÀÚ°¡¹é½Å ½ÃÀå Àü¸Á
Á¦10Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ÀÚ°¡¹é½Å ½ÃÀå Àü¸Á
Á¦11Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÚ°¡¹é½Å ½ÃÀå Àü¸Á
Á¦12Àå °æÀï ±¸µµ
- ½ÃÀå Á¡À¯À² ºÐ¼®, 2025³â
- ½ÃÀå ±¸Á¶
- ±â¾÷ °³¿ä(»ó¼¼ - °³¿ä, À繫, Àü·«, ÃÖ±Ù µ¿Çâ)
- Phibro Animal Health Corporation,
- Ceva
- Boehringer Ingelheim International GmbH
- Elanco
- Addison Biological Laboratory
- Bioveta, as
- Vaxxinova
- ARKO Laboratories
- Dopharma
- HIPRA
- Cambridge Technologies
- IDT Biologika.
- HYGIEIA BIOLOGICAL LABORATORIES
- Lohmann Breeders
- Design Biologix.
- Deltamune
- Bimeda(R) Biologicals
- Others
Á¦13Àå ºÎ·Ï
LSH
¿µ¹® ¸ñÂ÷
Persistence Market Research has recently released a comprehensive report on the worldwide market for Autogenous Vaccines. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global autogenous vaccines market from 2025 to 2032.
Key Insights:
- Autogenous Vaccines Market Size (2025E): USD 152.1 Million
- Projected Market Value (2032F): USD 219.7 Million
- Global Market Growth Rate (CAGR 2025 to 2032): 5.4%
Autogenous Vaccines Market - Report Scope:
Autogenous vaccines are custom-made vaccines developed for specific pathogens isolated from a particular individual or herd, primarily used in veterinary medicine. These vaccines play a vital role in controlling infectious diseases in livestock and companion animals when commercial vaccines are ineffective or unavailable. The market serves veterinary clinics, animal health centers, farms, and research laboratories, with increasing demand across poultry, swine, cattle, and aquaculture sectors. Market expansion is fueled by rising concerns over animal health, regulatory flexibility, and growing focus on precision veterinary care, particularly in regions where infectious disease outbreaks are common.
Market Growth Drivers:
The global autogenous vaccines market is driven by key factors including the increasing incidence of zoonotic and livestock diseases and the need for targeted, herd-specific immunization. These vaccines offer an effective solution for managing local strains of pathogens that may not be addressed by standard commercial vaccines. Rising demand for high-quality animal protein, enhanced livestock productivity, and consumer preference for antibiotic-free meat products further push the adoption of autogenous vaccines. Regulatory support and greater awareness among veterinarians and livestock owners regarding customized disease management also contribute to sustained market growth. Additionally, the growing aquaculture industry is generating new demand for species-specific autogenous vaccines.
Market Restraints:
Despite favorable growth trends, the autogenous vaccines market faces several restraints, including high production costs, extended timelines for vaccine development, and limited standardization in manufacturing practices. As these vaccines are tailor-made, the lack of mass production scalability can impact supply chain efficiency and cost-effectiveness. Furthermore, regulatory variations across different regions pose challenges for international trade and market expansion. Inadequate awareness about the benefits of autogenous vaccines among small-scale farmers, particularly in developing regions, and limited availability of advanced diagnostic tools for pathogen identification are additional hurdles to market penetration.
Market Opportunities:
The autogenous vaccines market presents significant opportunities driven by technological advancements in pathogen identification, vaccine formulation, and personalized veterinary care. The adoption of next-generation sequencing and molecular diagnostic tools enhances the speed and accuracy of pathogen profiling, facilitating rapid vaccine development. Growing emphasis on antimicrobial resistance reduction and the shift towards sustainable livestock farming open new growth avenues for autogenous vaccines. Strategic collaborations between veterinary vaccine manufacturers, diagnostic labs, and academic institutions are likely to expand the market's capabilities. Moreover, increasing government support for animal health initiatives and investment in veterinary infrastructure, especially in emerging markets, are expected to boost demand.
Key Questions Answered in the Report:
- What are the primary factors driving the growth of the autogenous vaccines market globally?
- Which animal segments and applications are most influenced by autogenous vaccine adoption?
- How are advancements in diagnostics and biotechnology impacting the development of autogenous vaccines?
- Who are the key players contributing to the autogenous vaccines market, and what strategies are they employing to maintain market relevance?
- What are the emerging trends and future prospects in the global autogenous vaccines market?
Competitive Intelligence and Business Strategy:
Leading players in the global autogenous vaccines market, including Ceva Sante Animale, Elanco Animal Health, and Phibro Animal Health Corporation, are emphasizing product customization, R&D investment, and geographic expansion to strengthen their market presence. These companies collaborate with veterinary professionals and research labs to develop herd-specific vaccines tailored to field-isolated pathogens. Investments in diagnostic technologies and integrated vaccine production platforms are enhancing speed-to-market and cost efficiency. Strategic acquisitions and regional partnerships further help key players expand their capabilities and penetrate untapped markets. Additionally, customer education initiatives and digital platforms are being leveraged to increase awareness and facilitate vaccine ordering and delivery.
Key Companies Profiled:
- Newport Laboratories, Inc. (Boehringer Ingelheim International GmbH)
- Elanco Animal Health
- Phibro Animal Health Corporation
- Ceva Sante Animale
- ACE Laboratory Services (Apiam Animal Health)
- Huvepharma, Inc.
- AniCon Labor GmbH
- Cambridge Technologies
- Dyntec s. r. o
- Hygieia Biological Laboratories
- HIPRA
- Vaxxinova
- sanphar (ipeve)
- Addison Biological Laboratory
- Zoetis (PHARMAQ AS)
- Barramundi Asia Pte Ltd.(UVAXX Asia)
- Kennebec River Biosciences
Key Segments Covered in Autogenous Vaccines Industry Research
Product:
- Bacterial Strain
- Virus Strain
By Animal Type
- Poultry
- Swine
- Fish
- Horses
- Others
End User:
- Veterinary Research Institutes
- Livestock Farming Companies
- Veterinary Clinics and Hospitals
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Table of Contents
1. Executive Summary
- 1.1. Global Autogenous Vaccines Market Snapshot, 2025-2032
- 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
- 1.3. Key Market Trends
- 1.4. Future Market Projections
- 1.5. Premium Market Insights
- 1.6. Industry Developments and Key Market Events
- 1.7. PMR Analysis and Recommendations
2. Market Overview
- 2.1. Market Scope and Definition
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
- 2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
- 2.4. COVID-19 Impact Analysis
- 2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
- 3.1. Product Adoption Analysis
- 3.2. Regulatory Landscape
- 3.3. Disease Epidemiology
- 3.4. Value Chain Analysis
- 3.5. Key Deals and Mergers
- 3.6. PESTLE Analysis
- 3.7. Porter's Five Force Analysis
4. Global Autogenous Vaccines Market Outlook:
- 4.1. Key Highlights
- 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
- 4.2. Market Size (US$ Mn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
- 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
- 4.3. Global Autogenous Vaccines Market Outlook: Strain Type
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Mn) and Analysis, By Strain Type, 2019-2024
- 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Strain Type, 2025-2032
- 4.3.3.1. Bacterial Strain
- 4.3.3.2. Viral Strain
- 4.3.4. Market Attractiveness Analysis: Strain Type
- 4.4. Global Autogenous Vaccines Market Outlook: Animal Type
- 4.4.1. Introduction / Key Findings
- 4.4.2. Historical Market Size (US$ Mn) Analysis, By Animal Type, 2019-2024
- 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Animal Type, 2025-2032
- 4.4.3.1. Poultry
- 4.4.3.2. Swine
- 4.4.3.3. Fish
- 4.4.3.4. Horses
- 4.4.3.5. Others
- 4.4.4. Market Attractiveness Analysis: Animal Type
- 4.5. Global Autogenous Vaccines Market Outlook: End User
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
- 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 4.5.3.1. Veterinary Clinics and Hospitals
- 4.5.3.2. Veterinary Research Institutes
- 4.5.3.3. Livestock Farming Companies
- 4.5.3.4. Aquaculture Farming
- 4.5.4. Market Attractiveness Analysis: End User
5. Global Autogenous Vaccines Market Outlook: Region
- 5.1. Key Highlights
- 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
- 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. East Asia
- 5.3.4. South Asia and Oceania
- 5.3.5. Latin America
- 5.3.6. Middle East & Africa
- 5.4. Market Attractiveness Analysis: Region
6. North America Autogenous Vaccines Market Outlook:
- 6.1. Key Highlights
- 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 6.2.1. By Country
- 6.2.2. By Strain Type
- 6.2.3. By Animal Type
- 6.2.4. By End User
- 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 6.3.1. U.S.
- 6.3.2. Canada
- 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Strain Type, 2025-2032
- 6.4.1. Bacterial Strain
- 6.4.2. Viral Strain
- 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Animal Type, 2025-2032
- 6.5.1. Poultry
- 6.5.2. Swine
- 6.5.3. Fish
- 6.5.4. Horses
- 6.5.5. Others
- 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 6.6.1. Veterinary Clinics and Hospitals
- 6.6.2. Veterinary Research Institutes
- 6.6.3. Livestock Farming Companies
- 6.6.4. Aquaculture Farming
- 6.7. Market Attractiveness Analysis
7. Europe Autogenous Vaccines Market Outlook:
- 7.1. Key Highlights
- 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 7.2.1. By Country
- 7.2.2. By Strain Type
- 7.2.3. By Animal Type
- 7.2.4. By End User
- 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 7.3.1. Germany
- 7.3.2. France
- 7.3.3. U.K.
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Russia
- 7.3.7. Turkey
- 7.3.8. Rest of Europe
- 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Strain Type, 2025-2032
- 7.4.1. Bacterial Strain
- 7.4.2. Viral Strain
- 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Animal Type, 2025-2032
- 7.5.1. Poultry
- 7.5.2. Swine
- 7.5.3. Fish
- 7.5.4. Horses
- 7.5.5. Others
- 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 7.6.1. Veterinary Clinics and Hospitals
- 7.6.2. Veterinary Research Institutes
- 7.6.3. Livestock Farming Companies
- 7.6.4. Aquaculture Farming
- 7.7. Market Attractiveness Analysis
8. East Asia Autogenous Vaccines Market Outlook:
- 8.1. Key Highlights
- 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 8.2.1. By Country
- 8.2.2. By Strain Type
- 8.2.3. By Animal Type
- 8.2.4. By End User
- 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Strain Type, 2025-2032
- 8.4.1. Bacterial Strain
- 8.4.2. Viral Strain
- 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Animal Type, 2025-2032
- 8.5.1. Poultry
- 8.5.2. Swine
- 8.5.3. Fish
- 8.5.4. Horses
- 8.5.5. Others
- 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 8.6.1. Veterinary Clinics and Hospitals
- 8.6.2. Veterinary Research Institutes
- 8.6.3. Livestock Farming Companies
- 8.6.4. Aquaculture Farming
- 8.7. Market Attractiveness Analysis
9. South Asia & Oceania Autogenous Vaccines Market Outlook:
- 9.1. Key Highlights
- 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 9.2.1. By Country
- 9.2.2. By Strain Type
- 9.2.3. By Animal Type
- 9.2.4. By End User
- 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 9.3.1. India
- 9.3.2. Southeast Asia
- 9.3.3. ANZ
- 9.3.4. Rest of South Asia & Oceania
- 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Strain Type, 2025-2032
- 9.4.1. Bacterial Strain
- 9.4.2. Viral Strain
- 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Animal Type, 2025-2032
- 9.5.1. Poultry
- 9.5.2. Swine
- 9.5.3. Fish
- 9.5.4. Horses
- 9.5.5. Others
- 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 9.6.1. Veterinary Clinics and Hospitals
- 9.6.2. Veterinary Research Institutes
- 9.6.3. Livestock Farming Companies
- 9.6.4. Aquaculture Farming
- 9.7. Market Attractiveness Analysis
10. Latin America Autogenous Vaccines Market Outlook:
- 10.1. Key Highlights
- 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 10.2.1. By Country
- 10.2.2. By Strain Type
- 10.2.3. By Animal Type
- 10.2.4. By End User
- 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 10.3.1. Brazil
- 10.3.2. Mexico
- 10.3.3. Rest of Latin America
- 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Strain Type, 2025-2032
- 10.4.1. Bacterial Strain
- 10.4.2. Viral Strain
- 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Animal Type, 2025-2032
- 10.5.1. Poultry
- 10.5.2. Swine
- 10.5.3. Fish
- 10.5.4. Horses
- 10.5.5. Others
- 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 10.6.1. Veterinary Clinics and Hospitals
- 10.6.2. Veterinary Research Institutes
- 10.6.3. Livestock Farming Companies
- 10.6.4. Aquaculture Farming
- 10.7. Market Attractiveness Analysis
11. Middle East & Africa Autogenous Vaccines Market Outlook:
- 11.1. Key Highlights
- 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 11.2.1. By Country
- 11.2.2. By Strain Type
- 11.2.3. By Animal Type
- 11.2.4. By End User
- 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 11.3.1. GCC Countries
- 11.3.2. Egypt
- 11.3.3. South Africa
- 11.3.4. Northern Africa
- 11.3.5. Rest of Middle East & Africa
- 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Strain Type, 2025-2032
- 11.4.1. Bacterial Strain
- 11.4.2. Viral Strain
- 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Animal Type, 2025-2032
- 11.5.1. Poultry
- 11.5.2. Swine
- 11.5.3. Fish
- 11.5.4. Horses
- 11.5.5. Others
- 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 11.6.1. Veterinary Clinics and Hospitals
- 11.6.2. Veterinary Research Institutes
- 11.6.3. Livestock Farming Companies
- 11.6.4. Aquaculture Farming
- 11.7. Market Attractiveness Analysis
12. Competition Landscape
- 12.1. Market Share Analysis, 2025
- 12.2. Market Structure
- 12.2.1. Competition Intensity Mapping by Market
- 12.2.2. Competition Dashboard
- 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. Phibro Animal Health Corporation,
- 12.3.1.1. Overview
- 12.3.1.2. Segments and Product Types
- 12.3.1.3. Key Financials
- 12.3.1.4. Market Developments
- 12.3.1.5. Market Strategy
- 12.3.2. Ceva
- 12.3.3. Boehringer Ingelheim International GmbH
- 12.3.4. Elanco
- 12.3.5. Addison Biological Laboratory
- 12.3.6. Bioveta, a.s.
- 12.3.7. Vaxxinova
- 12.3.8. ARKO Laboratories
- 12.3.9. Dopharma
- 12.3.10. HIPRA
- 12.3.11. Cambridge Technologies
- 12.3.12. IDT Biologika.
- 12.3.13. HYGIEIA BIOLOGICAL LABORATORIES
- 12.3.14. Lohmann Breeders
- 12.3.15. Design Biologix.
- 12.3.16. Deltamune
- 12.3.17. Bimeda(R) Biologicals
- 12.3.18. Others
13. Appendix
- 13.1. Research Methodology
- 13.2. Research Assumptions
- 13.3. Acronyms and Abbreviations
°ü·ÃÀÚ·á